Ligustilide-Treated Stem Cells for Stroke Therapy

Solution Overview

Problem

Current stem cell therapies for treating stroke have limited therapeutic effectiveness due to unfavorable survival rates of transplanted stem cells, primarily due to inflammatory reactions and inefficient homing and differentiation within the target tissue.

Innovation Solution

Treating stem cells with ligustilide in a culture medium to enhance the expression of differentiation-promoting genes, homing-promoting genes, and reduce inflammatory gene expression, thereby improving the therapeutic efficacy of stem cell treatments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If stem cells are transplanted into stroke patients, then therapeutic effect is provided, but survival rate of transplanted stem cells is unfavorable

Engineering Contradiction:

Improvesurvival rate of transplanted stem cellsVSAvoidinflammatory reactions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by pre-treating stem cells with ligustilide before transplantation to enhance their survival capabilities and reduce inflammatory responses. The stem cells are cultured with ligustilide for 24-48 hours prior to transplantation, which pre-adapts them to the inflammatory environment they will encounter in the stroke patient's body, thereby improving their survival rate and therapeutic effectiveness.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent utilizes parameter changes by modifying the chemical composition parameters of the culture medium through the addition of ligustilide. This substance alters the biochemical environment in which stem cells are cultured, leading to changes in gene expression profiles that enhance survival markers and reduce inflammatory markers, thus transforming the cellular parameters to improve post-transplantation outcomes.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If stem cells are transplanted into stroke patients, then therapeutic effect is provided, but homing efficiency to target tissue is inefficient

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidhoming efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary action by pre-treating stem cells with ligustilide before transplantation to enhance their survival capabilities and reduce inflammatory responses. The stem cells are cultured with ligustilide for 24-48 hours prior to transplantation, which pre-adapts them to the inflammatory environment they will encounter in the stroke patient's body, thereby improving their survival rate and therapeutic effectiveness.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent utilizes parameter changes by modifying the chemical composition parameters of the culture medium through the addition of ligustilide. This substance alters the biochemical environment in which stem cells are cultured, leading to changes in gene expression profiles that enhance survival markers and reduce inflammatory markers, thus transforming the cellular parameters to improve post-transplantation outcomes.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If conventional stem cell therapy is used, then treatment is provided, but differentiation capability in target tissue is insufficient

Engineering Contradiction:

Improvedifferentiation capabilityVSAvoidinflammatory gene expression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by pre-treating stem cells with ligustilide before transplantation to enhance their survival capabilities and reduce inflammatory responses. The stem cells are cultured with ligustilide for 24-48 hours prior to transplantation, which pre-adapts them to the inflammatory environment they will encounter in the stroke patient's body, thereby improving their survival rate and therapeutic effectiveness.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent utilizes parameter changes by modifying the chemical composition parameters of the culture medium through the addition of ligustilide. This substance alters the biochemical environment in which stem cells are cultured, leading to changes in gene expression profiles that enhance survival markers and reduce inflammatory markers, thus transforming the cellular parameters to improve post-transplantation outcomes.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9533012B2Method for enhancing therapeutic effect of stem cells

Publication Date: 2017.01.03 GWOXI STEM CELL APPL TECH CO LTD

AI summary

A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject in need an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.